ARCT

Arcturus Therapeutics Holdings Inc

Add to Watchlist

Advanced Chart

17.190

+0.49(2.934%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

17.700

Open

16.760

VWAP

17.33

Vol

371.04K

Mkt Cap

466.20M

Low

16.6761

Amount

6.43M

EV/EBITDA(TTM)

Total Shares

26.93M

256.45M

EV/OCF(TTM)

P/S(TTM)

3.71

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

19.95M

-32.09%

-0.626

+20.38%

15.58M

-31.57%

-0.951

-14.31%

18.92M

-54.6%

-0.762

+193.16%

Estimates Revision

The market is revising Upward the revenue expectations for Arcturus Therapeutics Holdings Inc. (ARCT) for FY2025, with the revenue forecasts being adjusted by 15.45% over the past three months. During the same period, the stock price has changed by 32.23%.

Revenue Estimates for FY2025

Revise Upward

+15.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-22.93%

In Past 3 Month

Stock Price

Go Up

+32.23%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 57.69 USD with a low forecast of 18.50 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 17.190

Low

18.50

Averages

57.69

High

140.00

Current: 17.190

Low

18.50

Averages

57.69

High

140.00

Leerink

Lili Nsongo

Outperform

downgrade

$63 -> $54

2025-08-22

Reason

Leerink

Lili Nsongo

Price Target

$63 -> $54

2025-08-22

downgrade

Outperform

Reason

Leerink analyst Lili Nsongo lowered the firm's price target on Arcturus Therapeutics to $54 from $63 and keeps an Outperform rating on the shares. The firm updated its COVID and Flu vaccine integrated market model to reflect lower US vaccination trends for both COVID and flu, the likely necessity for standalone mRNA flu vaccine approvals before approval of potential COVID/Flu mRNA combo vaccines, and regulatory uncertainties surrounding the development and approval path for COVID/Flu combination vaccines in light of the current FDA leadership position on mRNA vaccines positions, the analyst tells investors in a research note. The development strategy of both a combination COVID/Flu vaccine and a standalone flu vaccine remains unclear, and Leerink expects regulatory events, clinical data, and commercial contracting dynamics to drive strategic decisions by individual manufacturers.

Citi

Buy

maintain

$47 -> $49

2025-08-12

Reason

Citi

Price Target

$47 -> $49

2025-08-12

maintain

Buy

Reason

Citi raised the firm's price target on Arcturus Therapeutics to $49 from $47 and keeps a Buy rating on the shares. The firm believes the ARCT-032 Phase 2 readout in September offers a favorable risk/reward.

Wells Fargo

Overweight

downgrade

$45 -> $42

2025-08-12

Reason

Wells Fargo

Price Target

$45 -> $42

2025-08-12

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Arcturus Therapeutics to $42 from $45 and keeps an Overweight rating on the shares. The firm thinks setup ahead of next month's cystic fibrosis readout is favorable, given high proportion of CFTR null patients, high cumulative dose, and expectation of greater benefit with longer term dosing.

Scotiabank

Outperform

maintain

$32 -> $35

2025-07-02

Reason

Scotiabank

Price Target

$32 -> $35

2025-07-02

maintain

Outperform

Reason

Scotiabank raised the firm's price target on Arcturus Therapeutics to $35 from $32 and keeps an Outperform rating on the shares. The company presented favorable interim results for ARCT-810 in ornithine transcarbamylase, OTC, deficiency across two phase 2 studies, the analyst tells investors. Overall, the firm believes Arcturus' recent update validates the potential of the company's therapeutics programs, which Scotiabank notes are underappreciated and can provide substantial upside.

Citi

Overweight

maintain

$47

2025-07-01

Reason

Citi

Price Target

$47

2025-07-01

maintain

Overweight

Reason

Citi is adding an "upside 90-day catalyst watch" on Arcturus Therapeutics ahead of the Cystic Fibrosis catalyst expected in early Q3. The firm highlights potential upside on a Phase 2 readout from the company's CF program and keeps an Overweight rating and $47 price target on the shares.

Scotiabank

Greg Harrison

Outperform

initiated

$32

2025-05-28

Reason

Scotiabank

Greg Harrison

Price Target

$32

2025-05-28

initiated

Outperform

Reason

Scotiabank analyst Greg Harrison initiated coverage of Arcturus Therapeutics with an Outperform rating and $32 price target. The shares are trading near the company's cash position "with plenty of upside potential in the therapeutics pipeline," the analyst tells investors in a research note. The firm believes Arcturus shares are "significantly undervalued" given the potential of the company's therapeutics pipeline in cystic fibrosis and ornithine transcarbamylase deficiency.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcturus Therapeutics Holdings Inc (ARCT.O) is -5.83, compared to its 5-year average forward P/E of -9.50. For a more detailed relative valuation and DCF analysis to assess Arcturus Therapeutics Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.50

Current PE

-5.83

Overvalued PE

-1.15

Undervalued PE

-17.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.16

Current EV/EBITDA

-3.20

Overvalued EV/EBITDA

1.20

Undervalued EV/EBITDA

-5.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

12.90

Current PS

5.76

Overvalued PS

36.92

Undervalued PS

-11.12

Financials

Annual

Quarterly

FY2025Q2

YoY :

-43.24%

28.30M

Total Revenue

FY2025Q2

YoY :

-45.02%

-11.62M

Operating Profit

FY2025Q2

YoY :

-46.68%

-9.18M

Net Income after Tax

FY2025Q2

YoY :

-46.88%

-0.34

EPS - Diluted

FY2025Q2

YoY :

-81.11%

-5.76M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

+22.87%

-53.35

FCF Margin - %

FY2025Q2

YoY :

-6.05%

-32.44

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

249.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

14.6K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

211.8K

Volume

Months

6-9

128.8K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

249.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ARCT News & Events

Events Timeline

2025-08-11 (ET)

2025-08-11

16:03:42

Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)

2025-06-30 (ET)

2025-06-30

11:03:13

Arcturus announces 'positive' interim Phase 2 multiple dose data for ARCT-810

2025-05-12 (ET)

2025-05-12

16:05:52

Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)

News

3.0

09-01NASDAQ.COM

Is It a Good Time to Invest in Arcturus Therapeutics (ARCT) Following the Golden Cross?

Arcturus Therapeutics Holdings Inc. (ARCT) Overview

Technical Analysis: ARCT has recently shown a bullish signal with its 50-day simple moving average crossing above the 200-day simple moving average, a pattern known as a "golden cross." This technical indicator often suggests a potential breakout in stock price.
Golden Cross Explained: The golden cross occurs when a stock's short-term moving average surpasses its long-term moving average, typically indicating a reversal from a downtrend to an upward trend. This pattern consists of three stages: a downtrend, the crossover of moving averages, and a subsequent price increase.

Recent Performance and Outlook

Stock Performance: Over the past four weeks, ARCT shares have increased by 38.3%, indicating strong upward momentum. The stock currently holds a #3 (Hold) rating on the Zacks Rank, suggesting it may be on the verge of further gains.
Earnings Expectations: Analysts have noted positive changes in ARCT's earnings estimates, with four upward revisions in the last 60 days and no downward changes. This trend supports the bullish outlook for the stock.

Investment Recommendations

Future Potential: Given the positive technical indicators and earnings revisions, investors are encouraged to monitor ARCT for potential gains in the near future.
Top Stock Picks: Zacks Investment Research has identified five stocks with a high probability of gaining over 100% in the coming months. Among these, a satellite-based communications firm is highlighted as a top pick, with expectations of significant revenue growth as the space industry is projected to become a trillion-dollar market by 2025.
Historical Context: The article references past successful picks, such as Hims & Hers Health, which saw a remarkable increase of 209%, indicating the potential for high returns among Zacks' recommendations.

Additional Resources

Stock Analysis Report: A free stock analysis report for Arcturus Therapeutics Holdings Inc. is available for those interested in further details.
Zacks Investment Research: The article emphasizes the importance of staying updated with the latest stock recommendations from Zacks Investment Research.

9.5

08-13Benzinga

Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday

9.5

08-12Benzinga

Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday